Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.Glucagon-like peptide-1receptoragonistsgained approval as drugs to treat diabetes and obesity starting in the 2000s.
Researchers also suggested thatGLP-1receptoragonistsmay offer a promisingtherapeuticapproach, as they have the potential to address both obesity and alcohol use disorder simultaneously.
Background: Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1)receptoragonist, is being investigated as a treatment for obesity. Methods: In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily...
Furthermore, visual representations like the one above help us fully grasp the concept of Dental Caries Glp 1 Receptor Agonist Therapy.
The first and only GIP andGLP-1receptoragonistindicated to improve glycemic control in adults with type 2 diabetes.
The successful management ofdentalcariesrelies upon assessment of thecariesrisk of the individual and a treatment plan with personalizedtherapythat is derived from the details recorded in the risk assessment [13–18].
In pediatricdentistry, different methods ofcariesprevention and treatment are used: fissure sealing, remineralizingtherapyand the classic method of filling milk teeth in children.
In this videoIexplain howcariesdevelop, what STEPHAN CURVE is, Modified Keyes diagram .. and the four factors responsible forcaries..00:00 Introduction0...
SyntheticGLP-1receptoragonistsare variably resistant to degradation by the enzyme DPP-4, and therefore have a longer half-life, facilitating clinical use. Longer-actingGLP-1receptoragonistscan be administered once daily or once weekly.
